Meet Medicilon at the 4th SMC x AimedBio ADC Conference in Seoul | ADC Preclinical R&D Excellence
We are pleased to announce that Medicilon will attend the 4th SMC x AimedBio ADC Conference – a specialized gathering focused on the latest advances in antibody‑drug conjugates, bringing together leading researchers, drug developers, and industry experts from across the globe.
Venue:The Westin Seoul Parnas, South Korea – Medicilon Booth #6
Date: August 27-28, 2026
This conference provides an ideal platform to explore cutting‑edge ADC technologies and therapeutic strategies. We look forward to meeting you in Seoul and sharing how our integrated precnical ADC platforms can accelerate your program from concept to IND.
Meet our team on site
- Dr. Tai‑Wei Li – Vice President of Drug Discovery
- Junhong Xu – Vice President of Business Development
What We Highlight at SMC x AimedBio – ADC R&D Platforms
With 36 ADC IND approvals successfully supported for our clients (as of June 2026) and extensive experience across validated targets (Her2, Her3, Trop2, Claudin 18.2, CD33, Muc1, FR, and more), Medicilon offers a complete suite of preclinical ADC services under one roof.
Payloads & Linkers
- Comprehensive library of marketed payloads (DX8951f, SN‑38, DM1/DM4, Exatecan, Dxd, MMAE/MMAF, Tubulysin M, PBD dimer, etc.) and custom synthesis
- Cleavable/uncleavable and hydrophilic/hydrophobic linkers, including GGFG, VC‑PAB, SMCC, and N‑SMP
Conjugation & QC
- Conjugation at 5 mg, 50 mg, and 500 mg scales, with 2‑4 week turnaround
- DAR evaluation via HPLC and LC‑MS/MS; QC methods include SEC, HIC, and LC‑MS
In Vitro & In Vivo Pharmacology
- Over 300 cancer cell lines for binding, internalization, cytotoxicity, and apoptosis assays
- 800+ tumor models (CDX, PDX, syngeneic, humanized, orthotopic) across rodent and non‑rodent species
PK & Safety Assessment
- Comprehensive PK analysis for conjugated/total antibody, free payload, and ADA (LBA & LC‑MS/MS)
- Safety studies compliant with ICH S6 & S9 and NMPA/FDA/OECD/TGA requirements
Beyond ADC – Let’s Talk About Your Full Program
While our booth highlights ADC capabilities, Medicilon also provides biology, pharmacology, CMC, and regulatory support as part of our integrated preclinical CRO services. With over 22 years of experience, 2,000+ client R&D programs supported globally, and 690+ IND approvals worldwide (FDA, NMPA, EMA, TGA, MFDS, PMDA), we are ready to partner with you on every step from hit to IND – beyond ADC.
Come talk to the Medicilon team – we would be happy to discuss how we can support your specific project needs.
See you in Seoul!
